Literature DB >> 16311856

Comparison of resected and non-resected intraductal papillary mucinous neoplasms of the pancreas.

Shin-E Wang1, Yi-Ming Shyr, Tien-Hua Chen, Cheng-Hsi Su, Tsann-Long Hwang, Kuo-Shyang Jeng, Jui-Hao Chen, Chew-Wun Wu, Wing-Yiu Lui.   

Abstract

By comparing the clinicopathological features and survivals between the resected and non-resected intraductal papillary mucinous neoplasms (IPMNs) of the pancreas, this study tried to clarify the natural history of IPMNs, to provide a strategy for treatment, and to determine the justification of not performing resection for some patients. A total of 57 patients with IPMN, including 39 resected and 18 non-resected IPMNs, were recruited for study. Data on demographics, clinical presentations, diagnostic work-up, treatment modality, clinical course, and outcomes were evaluated and compared between the resected and non-resected IPMNs. The most common clinical presentation was abdominal pain (57% in total IPMNs, 67% in resected, 33% in non-resected), followed by body weight loss (32% in total IPMNs, 33% in resected, 28% in non-resected). The sensitivity in the diagnosis of IPMN was highest by magnetic resonance cholangiopancreatography (MRCP) (88%), followed by endoscopic retrograde cholangiopancreatography (ERCP) (68%), and computed tomography scan (CT scan) (42%) and sonography (10%). The median survival was 21.5 months for patients with resected IPMNs, ranging from 2 to 124 months, and 14 months in non-resected IPMN patients, ranging from 5.5 to 70 months. There is no significant survival difference between the resected and non-resected groups, with a 5-year survival of 69.8% in resected IPMNs and 59.8% in non-resected IPMNs, P = 0.347. The survival outcome of the unresectable non-resected IPMNs was much inferior to the resected IPMNs, P = 0.002 and resectable non-resected IPMNs, P = 0.001. Thus, the prime prognostic factor in predicting the survival outcome of IPMNs is resectability, instead of resection itself. Long-term survival could also be expected in resectable IPMNs without resection. No resection for the IPMN may be justified for patients with high surgical risks, especially for those who are asymptomatic and very aged.

Entities:  

Mesh:

Year:  2005        PMID: 16311856     DOI: 10.1007/s00268-005-0035-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

1.  Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients.

Authors:  Carlos Fernández-del Castillo; Javier Targarona; Sarah P Thayer; David W Rattner; William R Brugge; Andrew L Warshaw
Journal:  Arch Surg       Date:  2003-04

2.  Outcome after surgical resection of intraductal papillary and mucinous tumors of the pancreas.

Authors:  E Cuillerier; C Cellier; L Palazzo; J Devière; P Wind; F Rickaert; P H Cugnenc; M Cremer; J P Barbier
Journal:  Am J Gastroenterol       Date:  2000-02       Impact factor: 10.864

3.  Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas.

Authors:  Massimo Raimondo; Issei Tachibana; Raul Urrutia; Lawrence J Burgart; Eugene P DiMagno
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

4.  Surgical treatment of intraductal papillary-mucinous tumors of the pancreas.

Authors:  N Kanazumi; A Nakao; T Kaneko; S Takeda; A Harada; S Inoue; T Nagasaka; N Nakashima
Journal:  Hepatogastroenterology       Date:  2001 Jul-Aug

5.  Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.

Authors:  F Maire; P Hammel; B Terris; F Paye; J-Y Scoazec; C Cellier; M Barthet; D O'Toole; P Rufat; C Partensky; E Cuillerier; P Lévy; J Belghiti; P Ruszniewski
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 6.  An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.

Authors:  Ralph H Hruban; Kyoichi Takaori; David S Klimstra; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Sandra A Biankin; Carolyn Compton; Noriyoshi Fukushima; Toru Furukawa; Michael Goggins; Yo Kato; Gunter Klöppel; Daniel S Longnecker; Jutta Lüttges; Anirban Maitra; G Johan A Offerhaus; Michio Shimizu; Suguru Yonezawa
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

7.  Clinicopathological features of malignant intraductal papillary mucinous tumors of the pancreas: the differential diagnosis from benign entities.

Authors:  Manabu Kawai; Kazuhisa Uchiyama; Masaji Tani; Hironobu Onishi; Hiroyuki Kinoshita; Masaki Ueno; Takashi Hama; Hiroki Yamaue
Journal:  Arch Surg       Date:  2004-02

Review 8.  Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms.

Authors:  Y M Shyr; C H Su; S H Tsay; W Y Lui
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

9.  Comparison of resectable and unresectable periampullary carcinomas.

Authors:  Y M Shyr; C H Su; H C Wang; S S Lo; W Y Lui
Journal:  J Am Coll Surg       Date:  1994-04       Impact factor: 6.113

10.  Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

View more
  13 in total

Review 1.  Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis.

Authors:  Robert Grützmann; Stefan Post; Hans Detlev Saeger; Marco Niedergethmann
Journal:  Dtsch Arztebl Int       Date:  2011-11-18       Impact factor: 5.594

2.  Intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Jose G Trevino; N Joseph Espat; W Scott Helton
Journal:  Curr Treat Options Gastroenterol       Date:  2006-09

3.  A new approach to managing intraductal papillary mucinous pancreatic neoplasms.

Authors:  Paula Ghaneh; John Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

4.  Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms.

Authors:  Bin Xu; Wei-Xing Ding; Da-Yong Jin; Dan-Song Wang; Wen-Hui Lou
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

5.  Prognosis of cancer with branch duct type IPMN of the pancreas.

Authors:  Nobuhito Ikeuchi; Takao Itoi; Atsushi Sofuni; Fumihide Itokawa; Takayoshi Tsuchiya; Toshio Kurihara; Kentaro Ishii; Shujiro Tsuji; Junko Umeda; Fuminori Moriyasu; Akihiko Tsuchida; Kazuhiko Kasuya
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

Review 6.  Increased risk of second malignancy in pancreatic intraductal papillary mucinous tumors: Review of the literature.

Authors:  Gian Luca Baiocchi; Sarah Molfino; Barbara Frittoli; Graziella Pigozzi; Federico Gheza; Giacomo Gaverini; Antonio Tarasconi; Chiara Ricci; Francesco Bertagna; Luigi Grazioli; Guido A M Tiberio; Nazario Portolani
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

Review 7.  Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment.

Authors:  Robert Grützmann; Marco Niedergethmann; Christian Pilarsky; Günter Klöppel; Hans D Saeger
Journal:  Oncologist       Date:  2010-12-08

Review 8.  Diagnosis and management of relapsing pancreatitis associated with cystic neoplasms of the pancreas.

Authors:  William-R Brugge
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

Review 9.  F18-FDG-PET/CT for evaluation of intraductal papillary mucinous neoplasms (IPMN): a review of the literature.

Authors:  Francesco Bertagna; Giorgio Treglia; Gian Luca Baiocchi; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2013-01-12       Impact factor: 2.374

10.  Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Mathieu Daudé; Fabrice Muscari; Camille Buscail; Nicolas Carrère; Philippe Otal; Janick Selves; Louis Buscail; Barbara Bournet
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.